Hims & Hers Health (HIMS) Q2 2026: Revenue Soars 38% Fueled by AI-Driven Growth and Global Expansion
Hims & Hers accelerated its subscriber growth and international footprint, leveraging AI investments to deepen customer engagement and operational efficiency. The company’s strategic pivot in weight loss and expansion into complex specialties underpin a re-accelerating U.S. business and rapid global scaling. Elevated guidance and ongoing AI innovation signal sustained momentum and margin improvement potential.
Summary
- AI-Powered Platform Evolution: The company is transforming the customer experience through integrated AI, enhancing engagement and operational efficiency.
- Global Scale Amplifies Growth: International markets now contribute significantly, with multiple regions surpassing $100 million annualized revenue.
- Strategic Specialty Expansion: New categories like testosterone and peptides are rapidly scaling, supported by robust infrastructure and clinical expertise.
Business Overview
Hims & Hers Health operates a global digital health and wellness platform delivering personalized care through online sales of prescription and non-prescription products, medical consultations, and subscription services. The company’s major segments include its U.S. operations and rapidly growing international markets, with specialties spanning weight loss, sexual health, hormonal health, and emerging categories such as peptide therapies.
Performance Analysis
In the second quarter of 2026, Hims & Hers reported revenue of approximately $753 million, marking a 38% year-over-year increase driven by strong subscriber growth and international expansion. The subscriber base reached nearly 2.9 million, a 19% increase, underscoring the platform’s broadening appeal. Domestic revenue grew 16% year-over-year to $622 million, while international revenue surged over 17-fold to $131 million, reflecting the impact of the Eucalyptus acquisition and organic growth.
Gross margin contracted to 64%, down from 76% in the prior year period, primarily due to the strategic shift towards branded weight loss products and expanding international presence, both of which carry lower margins. Despite this, adjusted EBITDA remained solid at $60 million, with an 8% margin, improving sequentially as operational leverage and AI-driven efficiencies began to offset margin pressures. Operating cash flow was temporarily negative, reflecting working capital investments tied to branded weight loss cohorts, but free cash flow is expected to normalize in the second half of the year.
- Subscriber Growth Drives Scale: Nearly 300,000 net new subscribers added, expanding the platform’s reach and data assets.
- International Expansion Accelerates: Eucalyptus contributed $40 million in Q2 revenue, with the UK, Australia, and Germany each exceeding $100 million annualized revenue.
- Margin Compression Reflects Strategic Investments: Lower gross margins reflect deliberate category and geographic shifts to fuel long-term growth.
Overall, the quarter illustrates a company balancing rapid growth and innovation with disciplined investment, positioning itself for sustained scale and profitability.
Executive Commentary
"We’re proving, quarter after quarter, that helping people feel great and delivering strong results aren’t mutually exclusive. As we rebuild the consumer health experience from the ground up with a doctor-led AI clinical engine, the depth and breadth of our relationships with customers worldwide has never been greater."
Andrew Dudum, Co-Founder & CEO
"Our domestic revenue growth accelerated to 16% year-over-year, and our international business grew more than 17-fold, strengthened by the close of our Eucalyptus acquisition. This momentum, combined with the efficiencies we're generating from our investments in AI and technology, positions us to make access to high touch, comprehensive care more affordable for our customers while also significantly expanding our reach internationally."
Yemi Okupe, CFO
Strategic Positioning
1. AI-Driven Care Model Transformation
Hims & Hers is embedding AI deeply into its platform to create a unified, personalized health experience that replaces traditional telehealth models. AI supports clinical workflows by handling routine inquiries and enabling earlier intervention, evidenced by a threefold increase in customer engagement and a 50% reduction in non-clinical support tasks within the Hers weight loss segment. This approach not only enhances patient adherence and outcomes but also drives operational cost savings that can be reinvested into growth and price competitiveness.
2. Expanding Specialty Portfolio with Infrastructure Leverage
The company’s robust infrastructure, including extensive pharmacy and lab facilities, enables rapid entry into complex categories like testosterone replacement therapy (TRT) and peptides. TRT is scaling quickly, poised to become the sixth U.S. specialty exceeding $100 million in annual revenue. Peptide therapies are being developed with clinical rigor and supply chain validation, positioning Hims & Hers to capitalize swiftly once regulatory clarity is achieved, especially given its unique U.S.-based API manufacturing capabilities.
3. Accelerating Global Market Penetration
Following the Eucalyptus acquisition, Hims & Hers has established leadership in key international markets such as the UK, Australia, Germany, Japan, and Canada. These markets now contribute materially to revenue and are on track to become profit centers. The company plans to introduce proven U.S. specialties overseas, leveraging Eucalyptus’s go-to-market strength, thereby broadening its global footprint and diversifying revenue sources beyond the U.S.
4. Strategic Partnerships Fuel Market Expansion
Collaborations with pharmaceutical innovators like Novo Nordisk have been instrumental in driving consumer interest and expanding access to branded weight loss medications. These partnerships enhance marketing efficiency and provide valuable data sharing opportunities to optimize patient adherence and treatment outcomes, creating a competitive moat around the platform’s metabolic health offerings.
5. Focused Capital Allocation for Sustainable Growth
The company is balancing aggressive investment in AI, international expansion, and specialty development with disciplined financial management. Newly established receivables facilities and convertible debt offerings strengthen liquidity, while a share repurchase program signals confidence in intrinsic value. Management emphasizes a one-year or less breakeven horizon for new investments, aiming to sustain strong free cash flow and adjusted EBITDA growth over the medium term.
Key Considerations
Hims & Hers is navigating a complex growth phase marked by rapid scale, category expansion, and technological innovation. Investors should consider the following:
- AI Integration as a Differentiator: The company’s AI-native platform is a strategic asset that could drive superior engagement, retention, and cost efficiency, but execution risk remains as the technology scales across specialties and geographies.
- Margin Dynamics Reflect Growth Investments: Gross margin compression is expected to persist due to the increasing weight of lower-margin branded products and international revenue, requiring investors to assess the sustainability of unit economics and long-term margin recovery.
- Regulatory Uncertainty in Peptides: Market entry for peptide therapies hinges on FDA rulemaking, introducing timing and compliance risks despite strong preparatory work.
- International Expansion Risks: While international markets offer significant growth, they currently operate near breakeven or moderate losses, necessitating careful capital deployment and market execution.
- Competitive Landscape and Partnerships: Collaborations with pharma leaders enhance market positioning but also require ongoing alignment and data sharing to sustain competitive advantage.
Risks
Hims & Hers faces regulatory uncertainty, particularly regarding peptide therapies and evolving FDA guidance. The company’s aggressive growth and investment strategy could pressure margins and cash flow in the near term. Additionally, international expansion entails execution risks, including market adoption variability and operational integration challenges. Litigation with the FTC adds legal risk, though management expresses confidence in its defense.
Forward Outlook
For Q3 2026, Hims & Hers expects revenue between $880 million and $900 million, reflecting 47% to 50% year-over-year growth, and adjusted EBITDA of $75 million to $95 million, implying a 9% to 11% margin. For full-year 2026, revenue guidance is raised to $3.1 billion to $3.3 billion, a 32% to 41% increase, with adjusted EBITDA forecast at $275 million to $325 million, maintaining a 9% margin. Management anticipates continued gross margin pressure due to category mix but expects operating leverage and AI efficiencies to drive margin improvement and cash flow generation in the second half.
Takeaways
Hims & Hers is executing a multi-dimensional growth strategy combining AI innovation, specialty diversification, and international expansion, supported by a strong balance sheet and strategic partnerships. The company’s ability to integrate AI into clinical workflows is enhancing both customer experience and operational efficiency, setting it apart in the digital health space. While margin pressures and regulatory uncertainties persist, the elevated guidance and robust subscriber growth reinforce confidence in the company’s trajectory toward its 2030 financial ambitions.
- Growth Engine Fueled by AI and Scale: AI-driven engagement and operational efficiencies underpin accelerating subscriber growth and retention, crucial for long-term value creation.
- Global Platform Expansion: International markets now represent a significant and growing portion of revenue, enhancing diversification and scale advantages.
- Investor Focus on Margin and Regulatory Developments: Monitoring margin trajectory amid category shifts and FDA decisions on peptides will be key to assessing risk and upside.
Conclusion
Hims & Hers delivered a strong second quarter marked by rapid revenue growth, expanding global presence, and pioneering AI integration in healthcare delivery. The company’s strategic investments position it well for sustained scale and profitability, though investors should remain attentive to margin dynamics and regulatory developments. Elevated guidance and operational momentum underscore confidence in the company’s long-term vision.
Industry Read-Through
Hims & Hers’s results highlight the growing importance of AI and integrated digital platforms in consumer healthcare, setting a benchmark for competitors aiming to blend technology with personalized care. The company’s international expansion reflects a broader trend of digital health globalization, suggesting that scalable, AI-enabled care models could redefine access worldwide. Additionally, partnerships with pharmaceutical innovators illustrate a new collaborative approach to market expansion and patient engagement, signaling shifts in how healthcare companies align to accelerate adoption of novel therapies.